NEWSROOM
Press Releases by Agendia
News
Press Releases
Agendia Announces Five Studies in Breast Cancer for Presentation at the American Society of Clinical Oncology 2012 Breast Cancer Symposium
AMSTERDAM, THE NETHERLANDS, and IRVINE, CA, September 13, 2012 – Agendia, an innovative molecular cancer diagnostics company and leader in personalized medicine, announced today that they will present five posters on genomic research studies in breast cancer Read More
Agendia Brings Together Thought Leaders in Molecular Diagnostics and Medical Oncology
IRVINE, CA and AMSTERDAM, THE NETHERLANDS, August 29, 2012 – Agendia, an innovative molecular cancer diagnostics company and leader in personalized medicine, conducted one of its premiere thought leadership events, “Present and Future Trends in Read More
Agendia Earns ISO Certification for Facilities in Amsterdam and Irvine
IRVINE, CA and AMSTERDAM, THE NETHERLANDS, August 20, 2012 – Agendia, an innovative molecular cancer diagnostics company and leader in personalized medicine, today announced that it has been granted the International Organization for Standardization (ISO) Read More
Agendia Appoints Dr. Stefan Glück to Chair Medical Advisory Board
IRVINE, CA and AMSTERDAM, THE NETHERLANDS, August 9, 2012 – Agendia, an innovative molecular cancer diagnostics company and leader in personalized medicine, today announced that Stefan Glück, MD, PhD, will lead the company’s Medical Advisory Read More
Agendia Welcomes Dr. Mark Gittleman to Expanding Medical Advisory Board
IRVINE, CA and AMSTERDAM, THE NETHERLANDS, July 10, 2012 – Agendia, an innovative molecular cancer diagnostics company and leader in personalized medicine, today announced that Dr. Mark Gittleman, Medical Director of Breast Care Specialists and Read More
Agendia Names Industry Veteran Glen Fredenberg CFO and Vice President of Finance
IRVINE, CA and AMSTERDAM, THE NETHERLANDS, July 9, 2012 – Agendia, an innovative molecular cancer diagnostics company and leader in personalized medicine, today announced a key addition to their executive team with the appointment of Read More
Agendia Announces Launch of ColoPrint for Colon Cancer Prognosis and Prediction
Agendia’s Microarray-based Gene Expression Profile Provides Critical Additional Information for Treatment Decisions for Stage II Colon Cancer Patients IRVINE, CA and AMSTERDAM, THE NETHERLANDS, June 1, 2012 – Agendia, an innovative molecular cancer diagnostics company Read More